Ketamine News and Research

RSS
Scopolamine drug: A rapid-acting antidepressant for depression symptoms

Scopolamine drug: A rapid-acting antidepressant for depression symptoms

Third party reexamination of Phase III study of Ereska meets primary endpoint

Third party reexamination of Phase III study of Ereska meets primary endpoint

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Arena Pharmaceuticals' lorcaserin demonstrates low abuse potential

Arena Pharmaceuticals' lorcaserin demonstrates low abuse potential

New findings suggest current system of classifying psychoactive drugs in UK may need to be revisited

New findings suggest current system of classifying psychoactive drugs in UK may need to be revisited

Scientists find how 4-HB is metabolized by the body

Scientists find how 4-HB is metabolized by the body

Ketamine use increasing faster than any other drug in the UK, shows research

Ketamine use increasing faster than any other drug in the UK, shows research

NYU Langone Medical Center to establish a schizophrenia research center with $10M NIMH grant

NYU Langone Medical Center to establish a schizophrenia research center with $10M NIMH grant

Ketamine shows rapid antidepressant effects

Ketamine shows rapid antidepressant effects

A negative mGluR5 allosteric modulator shows efficacy in treating acute migraine attacks

A negative mGluR5 allosteric modulator shows efficacy in treating acute migraine attacks

Cooling brain prevents cell death in young mice exposed to anesthesia

Cooling brain prevents cell death in young mice exposed to anesthesia

Link found between brain receptors and schizophrenia

Link found between brain receptors and schizophrenia

Lack of brain NMDA receptors linked to schizophrenia

Lack of brain NMDA receptors linked to schizophrenia

Researchers explore the antidepressant effects of ketamine

Researchers explore the antidepressant effects of ketamine

New strategy for developing antidepressants

New strategy for developing antidepressants

Alcohol is most common 'spiking' drug

Alcohol is most common 'spiking' drug

Faster-acting antidepressant medications

Faster-acting antidepressant medications

EpiCept to conduct Phase III study of EpiCept NP-1 for treatment of chemotherapy induced peripheral neuropathy

EpiCept to conduct Phase III study of EpiCept NP-1 for treatment of chemotherapy induced peripheral neuropathy

Animal studies shouldn't alter anesthesiology practice in newborns

Animal studies shouldn't alter anesthesiology practice in newborns

Drugs should be classified by the amount of harm that they do

Drugs should be classified by the amount of harm that they do